Physician profile
Christina J Hanson
NPI 1336351907
$381,026.84
in general payments reported to CMS, 2019-2025
28 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,903 · 2022: $38K · 2023: $36K · 2024: $98K · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Travel and Lodging: $52K · Consulting Fee: $49K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Food and Beverage: $19K · Honoraria: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $186,450.68 |
| Travel and Lodging | $52,103.28 |
| Consulting Fee | $49,252.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,775.00 |
| Food and Beverage | $18,753.45 |
| Honoraria | $1,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $117,153.59 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $53,553.99 | 2021-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43,904.52 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $40,537.76 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $25,422.68 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $24,264.69 | 2023-2025 | Wegovy, Ozempic |
| Phathom Pharmaceuticals, INC. | $20,901.10 | 2023-2025 | Voquezna, Voquezna Dual Pak, Voquezna Triple Pak |
| Ipsen Biopharmaceuticals, INC | $19,918.72 | 2023-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $17,067.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $3,194.43 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $2,906.83 | 2021-2025 | Livdelzi |
| Glaxosmithkline, LLC. | $2,750.00 | 2024-2025 | |
| Mirum Pharmaceuticals, INC. | $2,137.38 | 2025 | Livmarli |
| Evoke Pharma, INC. | $1,990.03 | 2021 | |
| Abbvie INC. | $1,823.48 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $1,151.57 | 2023-2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $465.63 | 2023-2024 | |
| Lilly USA, LLC | $394.09 | 2022-2025 | Omvoh |
| Bausch Health US, LLC | $325.00 | 2025 | |
| Celgene Corporation | $284.36 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $245.91 | 2022-2025 | Entyvio, Eohilia |
| Amgen INC. | $156.29 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Orphalan INC | $143.06 | 2023-2025 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $129.99 | 2022-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $121.36 | 2022 | |
| Pfizer INC. | $34.56 | 2022-2025 | |
| Qol Medical, LLC | $24.33 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $23.66 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.